NEW YORK, April 29, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Aurinia Pharmaceuticals Inc.
To receive updates on the lawsuit, fill out the
The lawsuit seeks to recover losses for shareholders who
purchased Aurinia Pharmaceuticals Inc. between May 7, 2021 and February 25, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
June 14, 2022 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, Aurinia Pharmaceuticals Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (i) Aurinia was experiencing declining revenues;
(ii) Aurinia's 2022 sales outlook for the Company's only product
which it offers for the treatment of adult patients with active
lupus nephritis, LUPKYNIS, would fall well short of expectations;
(iii) accordingly, the Company had significantly overstated
LUPKYNIS's commercial prospects; (iv) as a result, the Company had
overstated its financial position and/or prospects for 2022; and
(v) as a result, the Company's public statements were materially
false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE Jakubowitz Law